LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference.
The Company is scheduled to present on Thursday, January 12, 2023 at 9:45am Pacific Time (12:45pm Eastern Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at and can be accessed here. The webcast will be archived and available for replay for at least 30 days after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.
For more information, please visit or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.
CONTACT: Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
洛厄尔，马萨诸塞州，2023年1月5日(环球网)--快速微生物系统公司(纳斯达克代码：RFID)(以下简称公司)，一家提供关键任务自动化解决方案的创新生命科学技术公司，今天宣布，该公司将出席第41届世界卫生保健大会。ST一年一度的摩根大通医疗会议。
该公司定于2023年1月12日(星期四)太平洋时间上午9：45(美国东部时间下午12：45)提交报告。演讲的现场网络直播将在Rapid Micro BiosSystems投资者关系网站上提供，并可在此处访问。网络直播将被存档，并在活动结束后至少30天内可供重播。
关于快速微生物系统
快速微生物生物系统公司是一家创新的生命科学技术公司，提供关键任务自动化解决方案，以促进生物制剂、疫苗、细胞和基因疗法以及无菌注射剂等保健产品的高效制造和快速、安全释放。该公司的旗舰产品Growth Direct系统自动化和现代化了过时的手动微生物质量控制(“MQC”)测试工作流程，这些工作流程用于全球规模最大、最复杂的制药生产业务。Growth Direct系统将质量控制实验室带到了制造车间，释放了在线/在线MQC自动化的力量，以提供更快的结果、更高的准确性、更高的运营效率、更好地遵守数据完整性法规和更快的决策，客户依靠这些来确保重要保健产品的安全和一致供应。该公司总部设在马萨诸塞州洛厄尔，在美国设有工厂，在马萨诸塞州列克星敦、瑞士、德国和荷兰设有全球办事处。
欲了解更多信息，请访问网站，或在推特上或在LinkedIn上关注该公司。
媒体联系人：Media@RapidmicroBio.com媒体联系：媒体@RapidmicroBio.com媒体联系：Media@RapidmicroBio.com媒体联系：媒体@RapidmicroBio.com媒体联系：Media@RapidmicroBio.com媒体联系：媒体@RapidmicroBio.com媒体联系：Media@RapidmicroBio.com
